SRC - Wiki-MPM

Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
KDR	kinase insert domain receptor	Neurophilin interactions with VEGF and VEGFR VEGF binds to VEGFR leading to receptor dimerization Integrin cell surface interactions VEGFA-VEGFR2 Pathway VEGFA-VEGFR2 Pathway VEGFR2 mediated cell proliferation Signaling by membrane-tethered fusions of PDGFRA or PDGFRB	Sorafenib Sunitinib 1-{4-[4-Amino-6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-5-yl]phenyl}-3-[2-fluoro-5-(trifluoromethyl)phenyl]urea Cediranib Vatalanib XL999 TG-100801 XL820 CYC116 Ramucirumab Pegdinetanib RAF-265 ABT-869 IMC-1C11 Semaxanib Pazopanib Midostaurin Axitinib 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide N-(4-phenoxyphenyl)-2-[(pyridin-4-ylmethyl)amino]nicotinamide N-cyclopropyl-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamide 6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide N-(CYCLOPROPYLMETHYL)-4-(METHYLOXY)-3-({5-[3-(3-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-YL}AMINO)BENZENESULFONAMIDE N-[5-(ETHYLSULFONYL)-2-METHOXYPHENYL]-5-[3-(2-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-AMINE 3-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1H)-one 3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one N'-(6-aminopyridin-3-yl)-N-(2-cyclopentylethyl)-4-methyl-benzene-1,3-dicarboxamide N~4~-methyl-N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine Cabozantinib Regorafenib Ponatinib Lenvatinib Nintedanib Fostamatinib Erdafitinib Foretinib Ripretinib Pralsetinib
ADRB3	adrenoceptor beta 3	Adrenoceptors G alpha (s) signalling events ADORA2B mediated anti-inflammatory cytokines production	Amphetamine Bethanidine Olanzapine Norepinephrine Nortriptyline Propranolol Paroxetine Trimipramine Cryptenamine Alprenolol Terbutaline Salmeterol Pindolol Formoterol Salbutamol Ergoloid mesylate Isoprenaline Arbutamine Amiodarone Fenoterol Ephedra sinica root Mephentermine Clenbuterol Oxprenolol Celiprolol Nebivolol Amibegron Solabegron Droxidopa Bufuralol Bopindolol Bupranolol Mirabegron Racepinephrine Dihydroergocornine DL-Methylephedrine Dihydroergocristine Vibegron
EGFR	epidermal growth factor receptor	Signaling by ERBB2 Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Signaling by ERBB4 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling PIP3 activates AKT signaling Signaling by EGFR GRB2 events in EGFR signaling GAB1 signalosome SHC1 events in EGFR signaling EGFR downregulation GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling EGFR interacts with phospholipase C-gamma EGFR Transactivation by Gastrin Constitutive Signaling by Aberrant PI3K in Cancer Signal transduction by L1 Constitutive Signaling by EGFRvIII Inhibition of Signaling by Overexpressed EGFR RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis PTK6 promotes HIF1A stabilization Downregulation of ERBB2 signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Extra-nuclear estrogen signaling NOTCH3 Activation and Transmission of Signal to the Nucleus HCMV Early Events Estrogen-dependent nuclear events downstream of ESR-membrane signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants	Cetuximab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Alvocidib IGN311 Matuzumab Vandetanib Rindopepimut Canertinib Pelitinib Varlitinib AV-412 S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE PD-168393 Afatinib Osimertinib Necitumumab Foreskin keratinocyte (neonatal) Depatuxizumab mafodotin Icotinib Neratinib Dacomitinib Fostamatinib Zalutumumab Brigatinib Olmutinib Zanubrutinib Abivertinib	Choriocarcinoma Gastric cancer Bladder cancer Oral cancer Glioma Laryngeal cancer Cervical cancer Esophageal cancer
GRIN2B	glutamate ionotropic receptor NMDA type subunit 2B	EPHB-mediated forward signaling EPHB-mediated forward signaling Unblocking of NMDA receptors, glutamate binding and activation Unblocking of NMDA receptors, glutamate binding and activation Ras activation upon Ca2+ influx through NMDA receptor RAF/MAP kinase cascade Neurexins and neuroligins Synaptic adhesion-like molecules MECP2 regulates neuronal receptors and channels Activated NTRK2 signals through FYN Assembly and cell surface presentation of NMDA receptors Assembly and cell surface presentation of NMDA receptors Negative regulation of NMDA receptor-mediated neuronal transmission Long-term potentiation	Glutamic acid Tramadol Enflurane Atomoxetine Pentobarbital Methadone Secobarbital Meperidine Haloperidol Acamprosate Donepezil Guaifenesin Felbamate Memantine Phenobarbital Aripiprazole Tenocyclidine Prasterone Taurine Milnacipran EVT-101 Lumateperone Acetylcysteine Ketobemidone Gavestinel Ifenprodil Magnesium acetate tetrahydrate Magnesium carbonate Esketamine Esketamine Fluciclovine (18F)
GRIN2A	glutamate ionotropic receptor NMDA type subunit 2A	Unblocking of NMDA receptors, glutamate binding and activation Unblocking of NMDA receptors, glutamate binding and activation Neurexins and neuroligins Synaptic adhesion-like molecules MECP2 regulates neuronal receptors and channels Assembly and cell surface presentation of NMDA receptors Assembly and cell surface presentation of NMDA receptors Negative regulation of NMDA receptor-mediated neuronal transmission Long-term potentiation	Glutamic acid Glycine Tramadol Enflurane Atomoxetine Pentobarbital Methadone Secobarbital Meperidine Acamprosate Donepezil Guaifenesin Felbamate Memantine Halothane Phenobarbital Aripiprazole Tenocyclidine Prasterone Milnacipran Acetylcysteine Ketobemidone Gavestinel Magnesium acetate tetrahydrate Magnesium carbonate Esketamine Fluciclovine (18F)
PDE4D	phosphodiesterase 4D	DARPP-32 events G alpha (s) signalling events	Adenosine phosphate Caffeine Caffeine Dyphylline Iloprost Amrinone Roflumilast Piclamilast Rolipram 3,5-Dimethyl-1-(3-Nitrophenyl)-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester 2-[3-(2-Hydroxy-1,1-Dihydroxymethyl-Ethylamino)-Propylamino]-2-Hydroxymethyl-Propane-1,3-Diol Zardaverine 1-(4-Aminophenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester (S)-Rolipram Cilomilast (R)-Rolipram 3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester 1-(4-Methoxyphenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester Crisaborole Ibudilast Tetomilast Exisulind (4R)-4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one 3,5-DIMETHYL-1-PHENYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER 3-isobutyl-1-methyl-7H-xanthine 4-[8-(3-nitrophenyl)-1,7-naphthyridin-6-yl]benzoic acid Trapidil
PPARD	peroxisome proliferator activated receptor delta	Carnitine metabolism Regulation of pyruvate dehydrogenase (PDH) complex Nuclear Receptor transcription pathway Signaling by Retinoic Acid	alpha-Linolenic acid Icosapent Troglitazone Valproic acid Treprostinil Rosiglitazone Sulindac Bezafibrate Phthalic Acid Heptyl glucoside Oleic Acid cis-Vaccenic acid Elafibranor KD3010 Cardarine (2S)-2-{3-[({[2-fluoro-4-(trifluoromethyl)phenyl]carbonyl}amino)methyl]-4-methoxybenzyl}butanoic acid 2-({[3-(3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)phenyl]carbonyl}amino)benzoic acid Indeglitazar {4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy}acetic acid Clinofibrate Glycerin Fenofibric acid Fish oil
VDR	vitamin D receptor	Vitamin D (calciferol) metabolism Nuclear Receptor transcription pathway SUMOylation of intracellular receptors	Calcitriol Calcifediol Ergocalciferol Cholecalciferol Paricalcitol Dihydrotachysterol Alfacalcidol Calcipotriol Lexacalcitol Seocalcitol Cholesterol Inecalcitol Becocalcidiol CTA018 Eldecalcitol Elocalcitol Doxercalciferol (1R,3R)-5-[(2E)-3-{(1S,3R)-2,2,3-trimethyl-3-[6,6,6-trifluoro-5-hydroxy-5-(trifluoromethyl)hex-3-yn-1-yl]cyclopentyl}prop-2-en-1-ylidene]cyclohexane-1,3-diol 1,3-CYCLOHEXANEDIOL, 4-METHYLENE-5-[(2E)-[(1S,3AS,7AS)-OCTAHYDRO-1-(5-HYDROXY-5-METHYL-1,3-HEXADIYNYL)-7A-METHYL-4H-INDEN-4-YLIDENE]ETHYLIDENE]-, (1R,3S,5Z) Vitamin D Curcumin Curcumin sulfate	Tuberculosis Localized autosomal recessive hypotrichosis
IGF1R	insulin like growth factor 1 receptor	Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) IRS-related events triggered by IGF1R SHC-related events triggered by IGF1R Extra-nuclear estrogen signaling	Insulin human Insulin lispro Insulin glargine Insulin pork Mecasermin Insulin aspart Insulin detemir Insulin glulisine Phosphoaminophosphonic Acid-Adenylate Ester ATL1101 XL228 rhIGFBP-3 Linsitinib Teprotumumab (4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione 3-[5-(1H-IMIDAZOL-1-YL)-7-METHYL-1H-BENZIMIDAZOL-2-YL]-4-[(PYRIDIN-2-YLMETHYL)AMINO]PYRIDIN-2(1H)-ONE Somatrem Insulin degludec Cixutumumab Brigatinib Mecasermin rinfabate	Malignant pleural mesothelioma Synovial sarcoma
KIT	KIT proto-oncogene, receptor tyrosine kinase	PIP3 activates AKT signaling Signaling by SCF-KIT Signaling by SCF-KIT Regulation of KIT signaling Regulation of KIT signaling Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Dasatinib-resistant KIT mutants Imatinib-resistant KIT mutants KIT mutants bind TKIs Masitinib-resistant KIT mutants Nilotinib-resistant KIT mutants Regorafenib-resistant KIT mutants Signaling by kinase domain mutants of KIT Sunitinib-resistant KIT mutants Signaling by juxtamembrane domain KIT mutants Sorafenib-resistant KIT mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by extracellular domain mutants of KIT	Sorafenib Imatinib Dasatinib Sunitinib Phosphonotyrosine Nilotinib XL820 OSI-930 ABT-869 Pazopanib Midostaurin Regorafenib Ponatinib Lenvatinib Ancestim Fostamatinib Erdafitinib Amuvatinib Pexidartinib Ripretinib Avapritinib	Piebaldism Acute myeloid leukemia (AML)
RXRA	retinoid X receptor alpha	RORA activates gene expression BMAL1:CLOCK,NPAS2 activates circadian gene expression Recycling of bile acids and salts Synthesis of bile acids and bile salts Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol Synthesis of bile acids and bile salts via 27-hydroxycholesterol PPARA activates gene expression PPARA activates gene expression Carnitine metabolism Regulation of pyruvate dehydrogenase (PDH) complex Endogenous sterols Transcriptional activation of mitochondrial biogenesis Activation of gene expression by SREBF (SREBP) Transcriptional regulation of white adipocyte differentiation Transcriptional regulation of white adipocyte differentiation Nuclear Receptor transcription pathway Regulation of lipid metabolism by PPARalpha Circadian Clock SUMOylation of intracellular receptors Signaling by Retinoic Acid Activation of anterior HOX genes in hindbrain development during early embryogenesis NR1H2 & NR1H3 regulate gene expression linked to lipogenesis NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose Transcriptional regulation of granulopoiesis Transcriptional regulation of granulopoiesis NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis NR1H2 & NR1H3 regulate gene expression linked to gluconeogenesis	alpha-Linolenic acid Adapalene Bexarotene Rosiglitazone Acitretin Alitretinoin Etodolac Tretinoin Etretinate Bezafibrate Alfacalcidol Phthalic Acid Doconexent Oleic Acid Arachidonic Acid EVT-101 3,20-Pregnanedione 2-chloro-5-nitro-N-phenylbenzamide 1-BENZYL-3-(4-METHOXYPHENYLAMINO)-4-PHENYLPYRROLE-2,5-DIONE 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID Tributyltin
PDGFRB	platelet derived growth factor receptor beta	PIP3 activates AKT signaling Downstream signal transduction Signaling by PDGF Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	Becaplermin Sorafenib Imatinib Dasatinib Sunitinib XL999 XL820 Pazopanib Midostaurin Regorafenib Nintedanib Polaprezinc Trapidil Foreskin fibroblast (neonatal) Fostamatinib Erdafitinib Pexidartinib Ripretinib Pralsetinib	Glioma
ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	Regulation of actin dynamics for phagocytic cup formation Role of ABL in ROBO-SLIT signaling Role of ABL in ROBO-SLIT signaling Myogenesis Myogenesis RHO GTPases Activate WASPs and WAVEs HDR through Single Strand Annealing (SSA) Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Cyclin D associated events in G1 RUNX1 regulates transcription of genes involved in differentiation of HSCs RUNX2 regulates osteoblast differentiation FCGR3A-mediated phagocytosis Factors involved in megakaryocyte development and platelet production	ATP Imatinib Dasatinib N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide Nilotinib XL228 Bosutinib 2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}-N-[4-PROPYL-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE 1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA Myristic acid PD-166326 5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE 2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide Regorafenib Ponatinib Fostamatinib Brigatinib Radotinib	Chronic myeloid leukemia (CML) Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
ANXA1	annexin A1	G alpha (q) signalling events G alpha (i) signalling events Formyl peptide receptors bind formyl peptides and many other ligands Smooth Muscle Contraction Interleukin-4 and Interleukin-13 signaling	Amcinonide Fluocinolone acetonide Hydrocortisone Methylprednisolone Clobetasol propionate Budesonide Dexamethasone Hydrocortisone aceponate Hydrocortisone acetate Hydrocortisone butyrate Hydrocortisone cypionate Hydrocortisone phosphate Hydrocortisone probutate Hydrocortisone valerate Prednisolone phosphate Dexamethasone acetate Betamethasone phosphate
FLT3	fms related receptor tyrosine kinase 3	PI3K Cascade PIP3 activates AKT signaling Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling FLT3 Signaling FLT3 Signaling STAT5 Activation FLT3 mutants bind TKIs STAT5 activation downstream of FLT3 ITD mutants KW2449-resistant FLT3 mutants semaxanib-resistant FLT3 mutants crenolanib-resistant FLT3 mutants gilteritinib-resistant FLT3 mutants lestaurtinib-resistant FLT3 mutants midostaurin-resistant FLT3 mutants pexidartinib-resistant FLT3 mutants ponatinib-resistant FLT3 mutants quizartinib-resistant FLT3 mutants sorafenib-resistant FLT3 mutants sunitinib-resistant FLT3 mutants tandutinib-resistant FLT3 mutants linifanib-resistant FLT3 mutants tamatinib-resistant FLT3 mutants Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Negative regulation of FLT3 FLT3 signaling through SRC family kinases FLT3 signaling through SRC family kinases FLT3 signaling by CBL mutants	Sorafenib Sunitinib XL999 Tandutinib ABT-869 Lestaurtinib Midostaurin Ponatinib Nintedanib Fostamatinib Gilteritinib Brigatinib Fedratinib Amuvatinib Quizartinib Pexidartinib Pralsetinib	Acute myeloid leukemia (AML)
INSR	insulin receptor	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling IRS activation Signal attenuation Insulin receptor signalling cascade Signaling by Insulin receptor Insulin receptor recycling	Insulin human Insulin lispro Insulin glargine Insulin pork Mecasermin Insulin aspart Insulin detemir Insulin glulisine Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate NN344 AT1391 [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID Chromic chloride Insulin degludec Fostamatinib Brigatinib Mecasermin rinfabate	Rabson-Mendenhall syndrome Leprechaunism ; Donohue syndrome
MET	MET proto-oncogene, receptor tyrosine kinase	PIP3 activates AKT signaling Constitutive Signaling by Aberrant PI3K in Cancer Sema4D mediated inhibition of cell attachment and migration RAF/MAP kinase cascade MET Receptor Activation Negative regulation of MET activity PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling MET activates RAS signaling MET activates PI3K/AKT signaling MET activates PTPN11 MET activates PTK2 signaling InlB-mediated entry of Listeria monocytogenes into host cell InlB-mediated entry of Listeria monocytogenes into host cell MET interacts with TNS proteins MET activates RAP1 and RAC1 MET receptor recycling MET activates STAT3 MECP2 regulates neuronal receptors and channels	K-252a SGX-523 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide N-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide 2-(4-fluorophenyl)-N-{[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}acetamide N-(3-chlorophenyl)-N-methyl-2-oxo-3-[(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]-2H-indole-5-sulfonamide 3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol AMG-208 1-[(2-NITROPHENYL)SULFONYL]-1H-PYRROLO[3,2-B]PYRIDINE-6-CARBOXAMIDE Crizotinib Cabozantinib Capmatinib Fostamatinib Tivantinib Brigatinib Amuvatinib	Renal cell carcinoma Cholangiocarcinoma Gastric cancer
CA3	carbonic anhydrase 3	Reversible hydration of carbon dioxide	Topiramate Ethoxzolamide Sulpiride Celecoxib Benzthiazide Valdecoxib Cyclothiazide Methazolamide Acetazolamide Dorzolamide Zonisamide Diclofenamide Brinzolamide Ellagic acid Saccharin
THRB	thyroid hormone receptor beta	Nuclear Receptor transcription pathway SUMOylation of intracellular receptors	Liothyronine Levothyroxine Dextrothyroxine Amiodarone Liotrix [3,5-Dibromo-4-(4-Hydroxy-3-Phenethylcarbamoyl-Phenoxy)-Phenyl]-Acetic Acid KB-141 2-[4-(4-Hydroxy-3-Isopropyl-Phenoxy)-3,5-Dimethyl-Phenyl]-2h-[1,2,4]Triazine-3,5-Dione Tiratricol GC-24 Eprotirome MB07811 Sobetirome 1-(4-HEXYLPHENYL)PROP-2-EN-1-ONE Thyroid, porcine
ERBB2	erb-b2 receptor tyrosine kinase 2	Signaling by ERBB2 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling PIP3 activates AKT signaling GRB7 events in ERBB2 signaling Downregulation of ERBB2:ERBB3 signaling GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Constitutive Signaling by Aberrant PI3K in Cancer Sema4D induced cell migration and growth-cone collapse RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Downregulation of ERBB2 signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Constitutive Signaling by Overexpressed ERBB2 Drug-mediated inhibition of ERBB2 signaling Signaling by ERBB2 KD Mutants Resistance of ERBB2 KD mutants to trastuzumab Resistance of ERBB2 KD mutants to sapitinib Resistance of ERBB2 KD mutants to tesevatinib Resistance of ERBB2 KD mutants to neratinib Resistance of ERBB2 KD mutants to osimertinib Resistance of ERBB2 KD mutants to afatinib Resistance of ERBB2 KD mutants to AEE788 Resistance of ERBB2 KD mutants to lapatinib Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Drug resistance in ERBB2 TMD/JMD mutants	Trastuzumab Lapatinib IGN311 Trastuzumab emtansine Varlitinib AV-412 Pertuzumab Afatinib Tucatinib Tesevatinib Fostamatinib Brigatinib Margetuximab Zanubrutinib	Choriocarcinoma Pancreatic cancer Gastric cancer Bladder cancer Endometrial Cancer Ovarian cancer Cholangiocarcinoma Breast cancer Cervical cancer

Search Results for: SRC